Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2Phillip Pymm, Nicholas A. Gherardin, Kathryn C. Davidson et al.|iScience|2022Cited by 19
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccineGeorgia Deliyannis, Dale I. Godfrey, Nicholas A. Gherardin et al.|EBioMedicine|2023Cited by 17
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccineGeorgia Deliyannis, Dale I. Godfrey, Nicholas A. Gherardin et al.|medRxiv|2022Cited by 1